OOIR: Observatory of International Research

Papers

(The H4-Index of European Heart Journal-Cardiovascular Pharmacotherapy is 22. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Comments on—The noradrenaline dosing in the new 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure	71
Comparative cardiovascular and renal effectiveness of empagliflozin and dapagliflozin: Scandinavian cohort study	61
Interdisciplinary recommendations for recurrent hyperkalaemia: insights from the GUARDIAN-HK European Steering Committee	61
Early initiation of SGLT2 inhibitors after acute myocardial infarction	51
Sex-related differences in cardiovascular pharmacotherapy: fiction or fact? Why can’t we see the evidence?	46
Anticoagulation for the prevention of arterial thromboembolism in cancer patients by primary tumour site: a systematic review and meta-analysis of randomized trials	38
Effects of renin–angiotensin system blockers on outcomes from COVID-19: a systematic review and meta-analysis of randomized controlled trials	38
Associations of omega-3 fatty acids vs. fenofibrate with adverse cardiovascular outcomes in people with metabolic syndrome: propensity matched cohort study	37
The search for the holy grail: the balance between the risk of thrombosis and bleeding in patients	35
Prognostic benefit of glucagon-like peptide-1 receptor agonists addition to sodium-glucose cotransporter 2 inhibitors in patients with atherosclerotic cardiovascular disease and heart failure: a cohor	33
Current evidence and future perspective for the management of left-sided prosthetic valve thrombosis	32
Net clinical benefit of extended dual pathway inhibition according to baseline risk in patients with chronic coronary syndrome: a COMPASS substudy	31
Treatment with dual antiplatelet therapy after an acute coronary event may often be tailor-made for the patient	30
Editorial on incidence and outcomes of transient new onset atrial fibrillation complicating acute coronary syndromes: results from a systematic review and meta-analysis	29
Flecainide to prevent atrial arrhythmia after patent foramen ovale closure, Rationale and design of the randomized AFLOAT study	29
Need for more evidence of safety in the pharmacological therapy of anaemia in chronic kidney disease: a cardiovascular perspective	29
Edoxaban for 12 vs. 3 months in cancer-associated isolated distal deep vein thrombosis according to different doses: insights from the ONCO DVT study	29
Impact of transfusion strategy on platelet aggregation and biomarkers in myocardial infarction patients with anemia	27
Inhibition of interleukin-1 or -6 after myocardial infarction: pros, cons, and future perspectives	27
Anti-inflammatory pharmacotherapy in patients with cardiovascular disease	26
Safety and efficacy of early initiation of sodium-glucose cotransporter-2 inhibitors after an acute coronary syndrome event: a meta-analysis of randomized controlled trials	25
Efficacy and safety of P2Y12 inhibitor monotherapy after complex PCI: a collaborative systematic review and meta-analysis	25
Subcutaneous furosemide patch: heart failure decongestion ‘from the comfort of your home’	22
Management of patients with congenital bleeding disorders and cardiac indications for antithrombotic therapy	22